INDIGO Biosciences Launches Bradykinin Reporter Assays for Inflammation, Pain, and Vascular Disease Drug Discovery

▤ Summary

INDIGO Biosciences launched new Human Bradykinin B1 and B2 Receptor Reporter Assays for drug discovery programs in inflammation, pain, vascular disease, and related conditions. The assays support functional screening of receptor signaling in agonist and antagonist modes and help researchers generate reproducible pharmacology data earlier in discovery. INDIGO offers the assays as all-inclusive 96-well kits and also provides assay services for teams that want outsourced testing. The launch expands the company’s GPCR assay portfolio and targets biopharma and research organizations working on bradykinin-mediated disease pathways.

▦ Linked Companies